Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 326Neoplasm Metastasis 40Neoplasms 25Ovarian Neoplasms 18Advanced Breast Cancer 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Multiple Endocrine Neoplasia Type 1 5Carcinoma, Ovarian Epithelial 5Breast Diseases 5Neoplasms by Site 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Breast Neoplasm Female 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

pembrolizumab 91Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 25Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Fulvestrant × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡